Literature DB >> 23267965

[A case of breast cancer treated with neoadjuvant chemotherapy and segmentectomy].

Misato Iizuka1, Katsuhisa Enomoto, Kenichi Sakurai.   

Abstract

Here, we report the case of a 40-year-old woman who was discovered upon examination to have a lump in her left breast. Breast ultrasonography revealed a hypoechoic mass of size 2.5×2.5 cm, shaped irregularly with fine calcification in the left DE area. A needle biopsy was performed and the resulting pathological diagnosis was invasive cancer(apocrine carcinoma, T2N0M0, Stage IIA),negative for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor type 2(HER2). Neoadjuvant chemotherapy was then performed with docetaxel/cyclophosphamide (TC)(4 courses) and epirubicin/cyclophosphamide (EC)(4 courses), after which ultrasonography revealed a significant reduction in mass, with a hypoechoic area of 1.0 cm×1.0 cm. Using magnetic resonance imaging (MRI), the tumor- contrast enhancement effect disappeared after the TC therapy, but the strong tumor-contrast enhancement enhancement effect diffused after EC therapy. Left breast segmentectomy and axillary lymphadenectomy were performed, and the tumor disappeared. The effectiveness of the chemotherapy was judged to be grade 3, and there was no subsequent metastasis or recurrence.

Entities:  

Mesh:

Year:  2012        PMID: 23267965

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Sonography of Invasive Apocrine Carcinoma of the Breast in Five Cases.

Authors:  Kyung-Jin Seo; Yeong Yi An; In Yong Whang; Eun Deok Chang; Bong Joo Kang; Sung Hun Kim; Chang Suk Park; Jeong Soo Kim; Hyunjoo Hong
Journal:  Korean J Radiol       Date:  2015-08-21       Impact factor: 3.500

2.  Neoadjuvant targeted therapy for apocrine carcinoma of the breast: A case report.

Authors:  Ping Yang; Shu-Jia Peng; Yan-Ming Dong; Lin Yang; Zhen-Yu Yang; Xi-E Hu; Guo-Qiang Bao
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.